Black Diamond Therapeutics, INC 8-K filings

Black Diamond Therapeutics reported positive Phase 2 results for silevertinib in NSCLC, demonstrating significant CNS activity and no new brain metastases, alongside a cash runway extending into late 2028.

Black Diamond Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Black Diamond Therapeutics announced positive Phase 2 results for silevertinib in frontline NSCLC patients with EGFR non-classical mutations, showing a 15.2-month median progression-free survival.

Black Diamond Therapeutics reported Q1 2026 financial results, highlighting $118.3 million in cash and providing updates on its silevertinib clinical trials.

Black Diamond Therapeutics reported strong financial results for Q4 and full year 2025, driven by operational efficiencies and a significant increase in cash, alongside positive clinical updates for silevertinib.

Black Diamond Therapeutics announced positive preliminary Phase 2 data for silevertinib in 1L NSCLC and plans for a new Phase 2 trial in GBM, extending its cash runway into late 2028.

Black Diamond Therapeutics reported improved Q3 2025 financial results and anticipates key clinical data for silevertinib in non-classical EGFRm NSCLC this quarter.

Black Diamond Therapeutics announced positive second quarter 2025 financial results, including a significant reduction in net loss and extended cash runway, alongside completed enrollment for its Phase 2 silevertinib trial.

Black Diamond Therapeutics, Inc. announced the final voting results from its 2025 Annual Meeting of Stockholders, confirming the election of three Class II directors and the ratification of PricewaterhouseCoopers LLP as its independent auditor.

Black Diamond Therapeutics announces positive Q1 2025 financial results, highlighted by a licensing agreement and progress in clinical trials, particularly for BDTX-1535.

Black Diamond Therapeutics grants Servier Pharmaceuticals a worldwide license to develop and commercialize BDTX-4933, a small molecule targeting RAF/RAS-mutant solid tumors, for an upfront payment of $70 million and potential milestone payments up to $710 million.

Black Diamond Therapeutics announces its Q4 and full year 2024 financial results, highlighting progress with BDTX-1535 and providing a corporate update.

Black Diamond Therapeutics reported encouraging initial Phase 2 data for BDTX-1535 in EGFRm NSCLC patients and announced a corporate restructuring to extend its cash runway.

Black Diamond Therapeutics is restructuring to focus on its lead program BDTX-1535, deprioritizing BDTX-4933, and extending its cash runway into the second quarter of 2026.

Black Diamond Therapeutics reports encouraging initial Phase 2 results for BDTX-1535, showing robust anti-tumor activity in patients with recurrent EGFR-mutant non-small cell lung cancer.

Black Diamond Therapeutics announced its second quarter 2024 financial results and provided updates on its clinical programs, including BDTX-1535 and BDTX-4933.

Black Diamond Therapeutics held its 2024 Annual Meeting, approving an amendment to its charter to limit officer liability and electing two Class I directors.

Black Diamond Therapeutics announced its first quarter 2024 financial results and provided an update on its clinical programs, including the progress of BDTX-1535 and BDTX-4933.

Black Diamond Therapeutics has appointed two new members to its Board of Directors, while two existing members have resigned, effective April 10, 2024.

Black Diamond Therapeutics announced its 2023 financial results and provided updates on its clinical programs, including the initiation of a Phase 2 trial for BDTX-1535 in first-line NSCLC patients.

Rajeev Shah has resigned from Black Diamond Therapeutics' Board of Directors and Audit Committee, effective immediately, with no reported disagreements with the company.